Hereditary Angioedema Market is segmented By Type (Hereditary Angioedema Type I and Hereditary Angioedema Type II), By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administrat

Hereditary Angioedema Market is segmented By Type (Hereditary Angioedema Type I and Hereditary Angioedema Type II), By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)


Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.

Market Dynamics

Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.

Key features of the study
  • This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hereditary angioedema market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market
Market Segmentation
  • By Type Insights (Revenue, USD Bn, 2019 – 2031)
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • By Drug Class Insights (Revenue, USD Bn, 2019 – 2031)
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • By Route of Administration Insights (Revenue, USD Bn, 2019 – 2031)
  • Subcutaneous
  • Intravenous
  • Oral
  • By Distribution Channel Insights (Revenue, USD Bn, 2019 – 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Regional Insights (Revenue, USD Bn, 2019 – 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
  • Key Players Insights
  • CSL Behring
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Orchard Therapeutics plc.
  • Pharming Group N.V.
  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals
  • Arrowhead Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals
  • CENTOGENE N.V.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Hereditary Angioedema Market, By Type
Hereditary Angioedema Market, By Drug Class
Hereditary Angioedema Market, By Route of Administration
Hereditary Angioedema Market, By Distribution Channel
Hereditary Angioedema Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
Epidemiology
Pipeline Analysis
4. Hereditary Angioedema Market, By Type, 2019-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 - 2031
Segment Trends
Hereditary Angioedema Type I
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Hereditary Angioedema Type II
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Hereditary Angioedema Market, By Drug Class, 2019-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 - 2031
Segment Trends
C1 Esterase Inhibitor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Kallikrein Inhibitor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Bradykinin Receptor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Attenuated Androgens
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Hereditary Angioedema Market, By Route of Administration, 2019-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 - 2031
Segment Trends
Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Hereditary Angioedema Market, By Distribution Channel, 2019-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 - 2031
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Hereditary Angioedema Market, By Region, 2019 - 2031, (USD Bn)
Introduction
Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
South Africa
North Africa
Central Africa
9. Competitive Landscape
CSL Behring
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Takeda Pharmaceutical Company Limited
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Orchard Therapeutics plc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pharming Group N.V.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
BioCryst Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Ionis Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Attune Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Arrowhead Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Adverum Biotechnologies, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
KalVista Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
CENTOGENE N.V.
10. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
11. References and Research Methodology
References
Research Methodology
About us
*Browse 32 market data tables and 28 figures on 'Hereditary Angioedema Market' - Global forecast to 2031

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings